Understanding the AllTrials Campaign: Its Progress, Impact, and Ongoing Challenges

What Is the AllTrials Campaign and Why Was It Launched?

Launched in 2013, the AllTrials campaign became a defining movement in the fight for full transparency in clinical research. Led by Sense about Science, in collaboration with Ben Goldacre, BMJ, and Cochrane, AllTrials raised global awareness of the problem of hidden and unreported clinical trial results—particularly those with negative or inconclusive outcomes.

The core slogan, “All Trials Registered. All Results Reported.”, crystallized the campaign’s demands for better transparency, improved access to data, and global policy reform. The concern was not academic—non-publication of trial data leads to evidence gaps in medicine, flawed systematic reviews, biased clinical guidelines, and ultimately, suboptimal patient care.

Founding Members and Their Vision

The campaign’s founding members were influential: Cochrane brought its evidence synthesis legacy; BMJ added editorial authority; and Ben Goldacre, through Bad Pharma, revealed pharmaceutical industry shortcomings. The mission was clear:

• Ensure that all clinical trials are registered in a public database before patient recruitment begins
• Mandate reporting of all trial results, regardless of outcomes
• Encourage retrospective registration and disclosure of past trials
• Push for enforceable legislation across jurisdictions

The campaign filled a void left by slow-moving policy, calling out both public institutions and private sponsors for failing to disclose complete data sets.

Milestones Achieved by the Campaign

The AllTrials campaign has achieved significant global visibility and policy impact over the last decade:

• Over 750 organizations signed the AllTrials petition, including medical societies, research funders, and ethics boards
• EMA’s Policy 0070 and EU Clinical Trial Regulation (EU CTR 536/2014) emerged around the same period, supporting proactive disclosure
• Tools like the FDAAA TrialsTracker were developed to monitor sponsor compliance
• Major journals like The Lancet and BMJ made trial registration a prerequisite for publication

Some companies, such as GSK and Johnson & Johnson, pledged to publish trial results proactively. The UK Health Research Authority (HRA) enforced reporting of all trials approved after 2018.

Public Engagement and Open Data Advocacy

Beyond the policy sphere, AllTrials galvanized public support with a petition that received more than 90,000 signatures globally. This grassroots activism sent a clear message to sponsors and regulators: society demands accountability.

The campaign also aligned itself with broader open data and open science movements, promoting reusable datasets and transparency across disciplines. Many academic institutions were prompted to retrospectively register trials and update their result disclosure practices to avoid reputational harm.

Academic Impact and Journal Response

The campaign influenced academic policy significantly. The International Committee of Medical Journal Editors (ICMJE) reinforced its position on trial registration as a publication condition. Guidelines like CONSORT were updated to emphasize complete and timely results disclosure. Systematic reviews began flagging risk of bias due to missing data more aggressively.

Studies also started evaluating transparency metrics. For instance, a PLOS Medicine analysis in 2020 showed that trial reporting among top-tier research institutions improved post-AllTrials, though gaps remain in smaller, investigator-initiated studies.

Challenges and Barriers to Full Compliance

Despite its success, the campaign faces key barriers:

• Enforcement is weak – Legal penalties for non-compliance remain rare outside the U.S.
• Legacy data is inaccessible – Pre-2007 trials remain largely unpublished, and efforts to retrieve those datasets are underfunded
• Resource gaps at small sponsors – Investigator-led trials often lack administrative support for registration and reporting
• Lack of harmonization – Registries like ClinicalTrials.gov, EU CTR, and ICTRP differ in their formats, making global compliance complex

Efforts to address these gaps continue, with transparency advocates lobbying for tougher laws and better sponsor accountability scorecards. Projects like ClinicalStudies.in are helping train institutions in practical compliance tools and global registry management.

Ongoing Monitoring and Compliance Tools

Transparency monitoring has evolved with technology. Platforms like TranspariMED, EU TrialsTracker, and WHO’s ICTRP now offer dashboards to benchmark disclosure by sponsor, country, and funder. Some regulators have started naming and shaming non-compliant institutions, creating reputational incentives for transparency.

Meanwhile, institutions like PharmaValidation.in are developing SOPs and compliance templates for consistent reporting, reducing administrative burden on research sponsors.

Conclusion: A Campaign That Reshaped Clinical Research Norms

The AllTrials campaign permanently changed how clinical research is conducted, reviewed, and disseminated. From patient advocacy to policy reform and journal mandates, the campaign has made a lasting mark.

However, transparency is a continuous journey. The next decade will require stricter enforcement, smarter registries, and full data accessibility—especially in underrepresented regions. The AllTrials legacy remains a blueprint for future movements fighting for ethical, evidence-based science in public health.

To explore global guidelines aligned with AllTrials values, visit the ICH Quality Guidelines and related transparency publications from PharmaRegulatory.in.

Understanding Global Transparency Laws in Clinical Trials

The Rise of Clinical Trial Transparency

Transparency in clinical trials has become a global regulatory expectation, driven by the need for public accountability, scientific integrity, and ethical responsibility. Governments, health authorities, and international organizations are mandating disclosure of study details and results across all phases of research, regardless of outcome.

This shift toward public registries, mandatory results posting, and data sharing is reflected in policies such as the U.S. FDA Amendments Act (FDAAA 801), the European Union Clinical Trials Regulation (EU CTR 536/2014), and World Health Organization (WHO) transparency initiatives. The result is a complex matrix of global obligations, timelines, and formats that sponsors must navigate.

Key Regulations Driving Transparency

Here is a snapshot of major regulations influencing global disclosure:

• FDAAA 801 (U.S.): Requires registration and results reporting on ClinicalTrials.gov within 21 days of trial initiation and 12 months post primary completion for applicable clinical trials (ACTs).
• EU CTR: Mandates use of the Clinical Trials Information System (CTIS) with transparency features such as public release of protocols, lay summaries, and redacted clinical study reports.
• WHO Joint Statement (2017): Calls for trial registration before first patient in, results within 12 months, and inclusion in the WHO ICTRP platform.
• UK Health Research Authority (HRA): Enforces research transparency in the UK with annual compliance audits.

Each framework comes with its own enforcement mechanisms, penalties for noncompliance, and publication requirements, placing increased scrutiny on sponsor practices.

Transparency Expectations for Sponsors

Sponsors are expected to comply with transparency rules not only in their country of origin but also in countries where trials are conducted. This includes:

• Pre-trial registration on recognized platforms
• Timely posting of summary results and lay summaries
• Redaction of sensitive data per local data protection laws (e.g., GDPR)
• Publication of protocol and informed consent documents

For example, a trial conducted in the EU must follow CTIS requirements for uploading the protocol, IMPD, assessment report, and result documents within the CTIS portal. Visit the EMA CTIS portal for latest guidance.

Challenges in Cross-Border Compliance

Multinational trials pose unique challenges due to conflicting timelines, formats, and publication thresholds. A study might be required to publish its results within 12 months in the U.S., but 6 months in the EU for pediatric or non-commercial studies. Lay summary requirements vary in language and detail. Differences in redaction rules also create complexity in preparing unified result packages.

For example, a Phase 2 oncology trial conducted across the U.S., Germany, and Japan would require coordination across ClinicalTrials.gov, CTIS, and jRCT platforms. Errors in synchronization may trigger compliance flags or raise issues during GCP inspections.

Harmonization Efforts and Global Initiatives

To streamline transparency obligations, international bodies have launched several harmonization initiatives:

• WHO ICTRP: A global platform that aggregates trial registry data from more than 20 primary registries including ClinicalTrials.gov, EU-CTR, and others. Its purpose is to provide a single point of access for trial transparency data worldwide.
• International Clinical Trials Registry Platform (ICTRP): Aligns minimum data set standards for registry entries to enhance data comparability.
• TransCelerate’s Disclosure Harmonization Initiative: Proposes common formats and redaction guidance to reduce duplication of effort across sponsor companies.

Despite these efforts, true harmonization is still evolving. Sponsors must remain aware of registry-specific nuances and regulatory updates that may impact disclosure strategy.

Role of Clinical Trial Disclosure Teams

With the increasing complexity of regulations, many sponsors have established specialized Clinical Trial Disclosure (CTD) teams. These teams are responsible for managing:

• Protocol registration and maintenance
• Results posting and updates
• Redaction of documents
• Coordination with Medical Writing and Regulatory Affairs
• Compliance tracking and audit preparation

Tools such as internal compliance dashboards, calendar trackers, and version-controlled repositories help disclosure teams stay ahead of deadlines and audit risks. Platforms like PharmaGMP.in share best practices for regulatory submission coordination.

Transparency Audits and Enforcement Trends

Authorities have increased their focus on enforcement. The FDA has issued noncompliance notices under FDAAA 801, and the EU is expected to audit sponsor behavior via CTIS. Public databases also act as informal audit tools. Watchdogs such as TranspariMED and Cochrane maintain public scorecards of sponsor performance, highlighting non-reporting sponsors and pressuring for change.

For example, in 2022, several prominent universities in the U.S. were flagged for delayed posting on ClinicalTrials.gov. These reputational risks can affect funding, partnership credibility, and ethical standing.

Transparency Beyond Registries: Journals and Public Databases

Transparency doesn’t end with registry posting. Journals now require trial registration numbers for publication. Sponsors are also encouraged to share raw datasets and protocols via platforms like Vivli, Dryad, and ClinicalStudyDataRequest.com. Some agencies, like Health Canada and the EMA, have introduced public Clinical Data Publication (CDP) portals for full CSRs, further advancing open science.

Conclusion

Global clinical trial transparency is no longer optional. Sponsors must develop centralized strategies that ensure full compliance with evolving regulations across all jurisdictions. From CTIS to ClinicalTrials.gov, harmonizing data, respecting privacy laws, and delivering results on time are essential to regulatory success and ethical research conduct.

Continuous training, investment in disclosure tools, and collaboration with regulatory experts will help sponsors stay audit-ready and aligned with global expectations. Visit ClinicalStudies.in for more tutorials and disclosure process case studies, or refer to WHO transparency guidance for global policy updates.